Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors

NCT02628574 is registered in ClinicalTrials.gov with Leap Therapeutics, Inc. as lead sponsor.

NCT NCT02628574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02628574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors
Lead sponsor
Leap Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
July 14, 2020
Enrollment
109 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors